Table 2

Baseline demographics and disease characteristics in the six participants

Baseline SLE
SLE duration
at baseline
Baseline SLE
SLEDAI score
Week 24
SLEDAI score
130–35 year old femaleTransverse myelitis, alopecia, oral ulcers, pleuritis4.8 yearsHCQ, MMF, prednisone60
235–40 year old femaleArthritis, alopecia, oral ulcers9.9 yearsHCQ82
330–35 year old femaleArthritis, alopecia, peritonitis, angioedema10.5 yearsCyclosporine, prednisone6NA
425–30 year old femaleRash, oral ulcers, alopecia, low complement, +dsDNA abs, nephritis11.7 yearsHCQ, MMF, prednisone106
545–50 year old femaleRash, arthritis, oral ulcer8.7 yearsHCQ, prednisone80
635–40 year old femaleArthritis, low complement, +dsDNA abs, leucopenia3.9 yearsHCQ, MMF, AZA, prednisone115
  • Demographics of the participants is presented in column 2 with baseline lupus manifestations and disease duration are shown in columns 2 and 3. There was a wide range of disease manifestations and disease duration. Baseline medications, SLEDAI at baseline and SLEDAI at week 24 are presented in columns 5, 6 and 7.

  • AZA, azathioprine; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil.